.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX08_Linezolid.Linezolid .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XX08_Linezolid.Linezolid| name: | Linezolid |
| ATC code: | J01XX08 | route: | oral |
| n-compartments | 1 |
Linezolid is a synthetic antibiotic of the oxazolidinone class. It is primarily used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Linezolid is approved for clinical use and commonly prescribed for pneumonia, skin and soft tissue infections, and other severe bacterial infections.
Pharmacokinetic parameters in healthy adult volunteers aged 18-55 years after single and multiple dosing (oral and intravenous administration), both sexes.
Ubals, M, et al., & Mitjà, O (2024). Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. The Lancet. Infectious diseases 24(4) 404–416. DOI:10.1016/S1473-3099(23)00683-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38211601
Bock, M, et al., & Moser, C (2023). Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 77(2) 242–251. DOI:10.1093/cid/ciad168 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36947131
Sicard, M, et al., & Guen, CG (2015). Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. European journal of clinical pharmacology 71(5) 611–615. DOI:10.1007/s00228-015-1813-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25740677